Abstract 296P
Background
Despite the knowledge that HPV is responsible for high-grade CIN and cervical cancer, little is known about the use of therapeutic vaccines as treatment considering most studies are still in early stages. We aimed to synthesize and critically evaluate the evidence from clinical trials on the safety, efficacy, and immunogenicity of therapeutic vaccines in the treatment of patients with high-grade CIN associated with HPV.
Methods
A systematic review of clinical trials adhering to the PRISMA 2020 statement was undertaken in MEDLINE/PubMed, Embase, CENTRAL Cochrane, Web-of-Science, Scopus, and LILACS, with no data or language restriction. Primary endpoint related to the safety, efficacy, and immunogenicity of these vaccines were assessed by analyzing the adverse/toxic effects associated with the therapeutic vaccine administration; via histopathological regression of the lesion and/or regression of the lesion size and by viral clearance; and through the immunological response of individuals who received treatment compared to those who did not or before and after receiving the vaccine, respectively.
Results
A total of 1,184 studies were identified, and 16 met all criteria. Overall, the therapeutic vaccines were heterogeneous regarding their formulation, dose, intervention protocol and routes of administration making meta-analysis unfeasible. In most studies (n=15), the vaccines were safe and well tolerated, with clinical efficacy with regards to lesions and histopathological regression or viral clearance. In addition, 11 studies showed favorable immunological responses against HPV, and seven studies showed a positive correlation between immunogenicity and clinical response, indicating promising results that should be further investigated.
Conclusions
Therapeutic vaccines, although urgently needed for avoid progression of CIN 2/3 patients, still present sparse data, requiring greater investments in well-designed phase III RCT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
62P - Combination of chemotherapy with endocrinal therapy as upfront treatment of metastatic breast cancer in hormone receptor- positive, HER2 -negative disease: A phase II randomised clinical trial
Presenter: Mariam Saleh
Session: Poster Display
Resources:
Abstract
63P - Efficacy and safety of eribulin plus carboplatin combination for HER2-negative metastatic breast cancer
Presenter: Mengqian Ni
Session: Poster Display
Resources:
Abstract
64P - Unmet needs following metastatic breast cancer in a middle-income Asian country
Presenter: Nirmala Bhoo-Pathy
Session: Poster Display
Resources:
Abstract
66P - Utidelone-based therapy in metastatic solid tumors after failure of standard therapies: A prospective, multicenter, single-arm trial
Presenter: Jianjun Zhang
Session: Poster Display
Resources:
Abstract
67P - Efficacy and safety of trastuzumab biosimilar in HER2+ve metastatic breast cancer: A multicenter phase III study
Presenter: krishna Mohan
Session: Poster Display
Resources:
Abstract
68P - Neratinib in combination with fulvestrant and or palbociclib can overcome endocrine resistance in HER2-low/ ER+ breast cancer
Presenter: Maryam Arshad
Session: Poster Display
Resources:
Abstract
69P - A multicenter, retrospective, real-world study of inetetamab combined with pyrotinib and vinorelbine as treatment for HER2-positive metastatic breast cancer
Presenter: Nan Jin
Session: Poster Display
Resources:
Abstract
70P - Overall survival of eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: A phase II, single-arm clinical trial
Presenter: Kenichi Inoue
Session: Poster Display
Resources:
Abstract
71P - Efficacy and safety of disitamab vedotin after trastuzumab for HER2 -positive breast cancer: A real-world data of retrospective study
Presenter: Chao Li
Session: Poster Display
Resources:
Abstract
72P - Real-world data on the efficacy of T-DM1 biosimilar for the treatment of HER2-positive metastatic breast cancer patients: Outcomes from a single center retrospective study in India
Presenter: Kaushal Patel
Session: Poster Display
Resources:
Abstract